Evaluate Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 After Single Subcutaneous Injection in Healthy Chinese Volunteers

NCT07535775 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult Participants

Interventions

DRUG: BCD-261

Sponsor

SPH-BIOCAD (HK) Limited